(Q34530406)

2 August 2017

1 reference

title

Acquired hemophilia. (English)

1 reference

2 August 2017

0 references

Boggio LN

1

1 reference

2 August 2017

Green D

series ordinal

2

1 reference

2 August 2017

publication date

1 December 2001

1 reference

Reviews in Clinical and Experimental Hematology

2 August 2017

published in

1 reference

2 August 2017

volume

5

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

389-404; quiz following 431

1 reference

Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Acquired factor VIII inhibitors in nonhemophilic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Treatment of haemophilia in the United Kingdom 1981-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Antigenicity of putative phospholipid membrane-binding residues in factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Detection of two different anti-factor VIII/von Willebrand factor antibodies of the IgA class in a hemophilic patient with a polyclonal factor VIII inhibitor of the IgG class

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

The rapid development of an IgM inhibitor of porcine factor VIII in a patient with acquired haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Spontaneous inhibitors of factor VIII: kinetics of inactivation of human and porcine factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Management of haemophilia in patients with high-titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Pathways for self-tolerance and the treatment of autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Successful treatment of acquired hemophilia with oral immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Interferon-alpha treatment and formation of factor VIII antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Immune tolerance: a synopsis of the international experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Isolation and study of an acquired inhibitor of human coagulation factor V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Clinical Significance of Antibodies to Bovine and Human Thrombin and Factor V After Surgical Use of Bovine Thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Acquired factor V inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

A case of factor V inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Acquired factor XI inhibitor in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Spontaneous factor XI inhibitors. Seven additional cases and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Autoantibody against prothrombin aberrantly alters the proenzyme to facilitate formation of a complex with its physiological inhibitor antithrombin III without thrombin conversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

Structure of human factor VIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00049.X

10.1046/J.1468-0734.2001.00049.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference